CN101687850A - 作为腺苷受体拮抗剂的取代的嘧啶 - Google Patents

作为腺苷受体拮抗剂的取代的嘧啶 Download PDF

Info

Publication number
CN101687850A
CN101687850A CN200880016896A CN200880016896A CN101687850A CN 101687850 A CN101687850 A CN 101687850A CN 200880016896 A CN200880016896 A CN 200880016896A CN 200880016896 A CN200880016896 A CN 200880016896A CN 101687850 A CN101687850 A CN 101687850A
Authority
CN
China
Prior art keywords
compound
group
formula
base
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880016896A
Other languages
English (en)
Chinese (zh)
Inventor
陈永胜
M·穆尔贾尼
D·斯利
J·特列卢
张小虎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall SA filed Critical Almirall SA
Publication of CN101687850A publication Critical patent/CN101687850A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200880016896A 2007-03-21 2008-03-21 作为腺苷受体拮抗剂的取代的嘧啶 Pending CN101687850A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89619807P 2007-03-21 2007-03-21
US60/896,198 2007-03-21
PCT/US2008/057911 WO2008116185A2 (en) 2007-03-21 2008-03-21 Substituted pyrimidines as adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
CN101687850A true CN101687850A (zh) 2010-03-31

Family

ID=39734991

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880016896A Pending CN101687850A (zh) 2007-03-21 2008-03-21 作为腺苷受体拮抗剂的取代的嘧啶

Country Status (5)

Country Link
US (1) US20100249084A1 (enExample)
EP (1) EP2132197A2 (enExample)
JP (1) JP2010522214A (enExample)
CN (1) CN101687850A (enExample)
WO (1) WO2008116185A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102772800A (zh) * 2011-12-20 2012-11-14 同济大学 靶向腺苷受体a2bar的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
WO2015085909A1 (zh) * 2013-12-10 2015-06-18 苏州大学 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物
CN107286146A (zh) * 2017-07-05 2017-10-24 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4‑氨基嘧啶衍生物及其用途
CN109651358A (zh) * 2017-10-11 2019-04-19 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090136473A1 (en) 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
CA2722582A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf. Biaryl pde4 inhibitors for treating inflammation
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
PL3334431T3 (pl) 2015-08-11 2020-03-31 Novartis Ag 5-bromo-2,6-di-(1H-pirazol-1-ilo)pirymidyno-4-amina do zastosowania w leczeniu nowotworu złośliwego
WO2017178820A1 (en) 2016-04-15 2017-10-19 Oxford University Innovation Limited Adenosine receptor modulators for the treatment of circadian rhythm disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US78271A (en) * 1868-05-26 fatzingek
US27196A (en) * 1860-02-21 hitchcock
US3775326A (en) * 1972-04-17 1973-11-27 Addressograph Multigraph Pressure fixable electroscopic printing powder
JPS54115384A (en) * 1978-02-28 1979-09-07 Hokko Chem Ind Co Ltd Ryrazolyl pyrimidine derivative, and agricultural and horticultural fungicides
JPS54117029A (en) * 1978-02-28 1979-09-11 Hokko Chem Ind Co Ltd Agricultural and horticultural microbicide
JPS6059883B2 (ja) * 1978-05-08 1985-12-27 北興化学工業株式会社 農園芸用殺菌剤
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
DE3922735A1 (de) * 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
DE19836697A1 (de) * 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000027824A1 (en) * 1998-11-12 2000-05-18 Elan Pharmaceuticals Substituted pyrimidine compositions and methods of use
EP1261327B1 (en) * 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
MXPA05005477A (es) * 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
AU2004299461A1 (en) * 2003-12-15 2005-06-30 Almirall Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
ATE502936T1 (de) * 2005-04-11 2011-04-15 Almirall Sa 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102772800A (zh) * 2011-12-20 2012-11-14 同济大学 靶向腺苷受体a2bar的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
WO2015085909A1 (zh) * 2013-12-10 2015-06-18 苏州大学 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物
CN107286146A (zh) * 2017-07-05 2017-10-24 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4‑氨基嘧啶衍生物及其用途
CN107286146B (zh) * 2017-07-05 2020-07-31 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
CN109651358A (zh) * 2017-10-11 2019-04-19 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
CN109651358B (zh) * 2017-10-11 2023-04-07 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用

Also Published As

Publication number Publication date
WO2008116185A2 (en) 2008-09-25
JP2010522214A (ja) 2010-07-01
WO2008116185A3 (en) 2009-03-12
EP2132197A2 (en) 2009-12-16
US20100249084A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
KR101780784B1 (ko) 2,3-이치환된 1-아실-4-아미노-1,2,3,4-테트라하이드로퀴놀린 유도체 및 이의 브로모도메인 억제제로서의 용도
CN101687850A (zh) 作为腺苷受体拮抗剂的取代的嘧啶
CA2484209C (en) Protein kinase modulators and methods of use
JP4572194B2 (ja) 置換された８−パーフルオロアルキル−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オン誘導体
CN103641833A (zh) 作为蛋白激酶抑制剂的化合物和组合物
JP2010511727A (ja) アデノシン受容体アンタゴニストとしての置換ピリミジン
CN117222640A (zh) 作为fgfr抑制剂的杂环化合物及其应用
JP2010511727A5 (enExample)
WO2010030027A1 (en) Aromatic nitrogen-containing 6-membered ring compounds and their use
EP1951683A1 (en) Pyrimidine derivatives for the treatment of cancer
JP2008540622A (ja) 化合物
CN101305005A (zh) 新二氮杂螺烷以及它们用于治疗ccr8介导的疾病的用途
JP2019507766A (ja) 線維症の治療のための新規化合物及びその医薬組成物
WO2006118598A1 (en) Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
WO2017000277A1 (en) Substituted triazolo bicycliccompounds as pde2 inhibitors
CN109641912A (zh) 二环杂芳基衍生物
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
CN114401955A (zh) 细胞周期蛋白依赖性激酶的抑制剂
CN120530110A (zh) 杂环化合物、药物组合物及其应用
CN118632843A (zh) 一种吡啶类衍生物及其用途
JP2024510306A (ja) Ｃｔｌａ－４低分子分解剤及びその使用
HK40010332A (en) 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
JP2579701B2 (ja) 新規キノリン誘導体およびそれを有効成分として含有する制癌剤効果増強剤
HK40010332B (en) 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
CN101238116A (zh) 用作酪氨酸激酶抑制剂的吡唑基氨基嘧啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100331